Edgar Filing: ABIOMED INC - Form 4

ABIOMED INC Form 4 May 11, 2015 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Check this box if no longer subject to Section 17(a) of the Investment Company Act of 1940 Check this box if no longer subject to Section 17(a) of the Investment Company Act of 1940 Check this box if no longer subject to Section 17(a) of the Investment Company Act of 1940 Check this box if no longer subject to Section 17(a) of the Investment Company Act of 1940 Check this box if no longer subject to Section 17(a) of the Investment Company Act of 1940 Check this box if no longer subject to Section 17(a) of the Investment Company Act of 1940 Check this box if no longer subject to Section 17(a) of the Investment Company Act of 1940 Check this box if no longer subject to Section 17(a) of the Investment Company Act of 1940 Check this box if no longer subject to Section 17(a) of the Investment Company Act of 1940 Check this box if no longer subject to Section 17(a) of the Investment Company Act of 1940 Check this box if no longer subject to Section 11(b) Check the Investment Check the Inv											
(Print or Type Responses)											
PUHY DOROTHY E Symbol			er Name and Ticker or Trading MED INC [ABMD]				5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (of Earliest 7	Fransaction	1			c all applicable		
(Month/ C/O ABIOMED, INC., 22 CHERRY 05/07/2 HILL DRIVE				/Day/Year) /2015				_X_ Director10% Owner Officer (give titleOther (specify below) below)			
Filed(Mo				endment, Date Original onth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
	S, MA 01923	(Zip)						Person			
1.Title of Security (Instr. 3)	1.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if			a. 4. Securities Acquired (A) Transaction Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)					6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial	
				Code V	Amount	(A)or(D) Price		Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)		
Common Stock, \$0.01 par value	05/07/2015			S <u>(1)</u>	2,611 (1)	D	\$ 69.9971 (4)	70,617	D		
Common Stock, \$0.01 par value	05/07/2015			S <u>(1)</u>	403 <u>(1)</u>	D	\$ 70.8091 (5)	70,214	D		
Common Stock, \$0.01 par value	05/07/2015			S <u>(1)</u>	260 <u>(1)</u>	D	\$ 71.8516 (<u>6)</u>	69,954	D		

Edgar Filing: ABIOMED INC - Form 4

Common Stock, \$0.01 par value	05/07/2015	S <u>(1)</u>	128 <u>(1)</u>	D	\$ 73.0029 (7)	69,826	D
Common Stock, \$0.01 par value	05/07/2015	S <u>(1)</u>	22 <u>(1)</u>	D	\$ 73.7763 (8)	69,804	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) (2)	\$ 13.21					08/08/2007 <u>(9)</u>	08/09/2016	Common Stock	8,000
Stock option (right to buy) (2)	\$ 12.69					08/13/2008 <u>(9)</u>	08/08/2017	Common Stock	8,000
Stock Option (right to buy) (3)	\$ 18.63					08/12/2009 <u>(9)</u>	08/13/2018	Common Stock	13,500
Stock Option (right to buy) (3)	\$ 7.67					08/11/2010 <u>(9)</u>	08/12/2019	Common Stock	13,500

8. De Se (Ir Stock Option (right to buy) $\frac{(3)}{2}$ \$ 9.99

08/10/2011(9) 08/11/2020 Common Stock 13,500

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

X

PUHY DOROTHY E C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923

Signatures

/s/ Stephen C. McEvoy (by power of attorney)

**Signature of Reporting Person

Date

05/11/2015

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- (2) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- (3) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$69.5000
 (4) and \$70.4900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$70.5000(5) and \$71.3800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$71.5200
(6) and \$72.3900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$72.5300
(7) and \$73.4100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$73.5300(8) and \$73.9000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(9) This option becomes exerciseable in full on the date set forth in Table II, Column 6.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.